ArticlePloS one2025
Exploratory study of serum protein biomarkers for sudden cardiac arrest using protein extension assay: A case-control study.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBiomarkers associated with the occurrence of sudden cardiac arrest (SCA) are not currently utilized in clinical practice. We aimed to identify novel protein biomarkers associated with sudden cardiac arrest (SCA) using proteomic profiling and evaluate their predictive power alongside traditional cardiovascular risk factors.
methodsA total of 42 SCA patients with medical causes, aged ≤ 65 years and whose initial rhythm was shockable, and 42 age- and sex-matched controls were analyzed. The initial serum samples obtained after emergency department visits were used for SCA cases. Using a protein extension assay, we identified significant biomarkers through correlation analysis with SCA and extracted proteins with no or weak correlation with the initial lactate level and arrest-to-sampling time to account for post-cardiac arrest changes. The area under the receiver operating characteristic curve (AUROC) was calculated to assess the predictive performance of the extracted proteins.
resultsAmong the 246 distinct proteins that met quality criteria, 97 showed a strong correlation with SCA. Among these 97 proteins, 44 showed weak or no correlation with lactate levels, and 12 showed weak or no correlation with onset-to-sampling time. Two proteins (AXL receptor tyrosine kinase [AXL] and TIMP Metallopeptidase inhibitor 4 [TIMP-4]) met all the criteria for biomarker extraction. Both showed significant associations with SCA and enhanced predictive power when combined with traditional risk factors in multivariable analysis. The AUROC for the baseline model using traditional risk factors was 0.692 (95% confidence interval [CI] 0.578-0.806), which improved significantly with the addition of AXL and TIMP-4 (AUROC [95% CI] 0.891 [0.817-0.964] and 0.910 [0.910-0.997], respectively).
conclusionAXL and TIMP-4 may be crucial role in the early detection and risk assessment of SCA. Future research to verify the utility of AXL and TIMP-4 in large cohorts is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.